Vectura teams up with Propeller on inhaler plan

In a statement, Vectura said the plan was to use its dry powder inhaler technology with Propeller's FDA-cleared digital health platform to treat respiratory diseases.

“The initial focus of the collaboration will be the development of an add-on sensor for Vectura's lever-operated multi-dose inhaler (LOMI). Patients with a propeller-connected LOMI device will be more engaged with their care and better equipped to understand their disease and improve self-management,” Vectura said.

Vectura chief executive James Ward-Lilley said there adherence to therapy was one of the major issues driving poor maintenance management of chronic conditions.

“There is increasing evidence of the value of intelligent sensor technology significantly enabling a reduction of symptoms, including exacerbations and long term healthcare utilisation costs. This collaboration is a first step towards Vectura embracing a connected solution for all our devices," he said.